biotech · Relapsed/Refractory Multiple Myeloma · Relapsed/Refractory Autoimmune Diseases
Nanjing Legend Biotech
Nanjing Legend Biotech Co.
NovaPharmaNews editorial coverage mentioning Nanjing Legend Biotech — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- 2101 Cottontail Lane, Somerset, New Jersey 08873, US
- Employees
- 2,457
- Programs
- 36
- Drugs
- 17
- Patents
- 26
News & analysis
NovaPharmaNews articles mentioning Nanjing Legend Biotech — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning Nanjing Legend Biotech — regulatory, clinical, and market analysis.
Legend Biotech surges on early in vivo CAR-T data for lymphoma
Legend Biotech's experimental in vivo CAR-T therapy, LB2501, reduced or eliminated disease signs in all treated lymphoma patients in a first-in-human trial. The data fuel hopes that the approach could compete with ex vivo therapies like Novartis' Kymriah.
Legend Biotech Presents Promising CARVYKTI and LB2102 Data at ASCO
Legend Biotech has presented significant new data at ASCO 2026, showcasing updated survival and safety results for its multiple myeloma therapy CARVYKTI from the CARTITUDE-4 study. The company also unveiled first-in-human data for its investigational CAR-T cell therapy, LB2102, targeting solid tumors.